Primary Sclerosing Cholangitis - Pipeline Review, H1 2018 - Product Image

Primary Sclerosing Cholangitis - Pipeline Review, H1 2018

  • ID: 4451660
  • Report
  • 106 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Acorda Therapeutics Inc
  • Allergan Plc
  • DURECT Corp
  • iCo Therapeutics Inc.
  • Sancilio & Company Inc
  • Shire Plc
  • MORE
Primary Sclerosing Cholangitis - Pipeline Review, H1 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H1 2018, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape.

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 4, 6 and 1 respectively.

Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis (Gastrointestinal)
  • The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
  • The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects
  • The pipeline guide evaluates Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal)
  • Classify potential new clients or partners in the target demographic
  • Develop tactical initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics
  • Formulate corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acorda Therapeutics Inc
  • Allergan Plc
  • DURECT Corp
  • iCo Therapeutics Inc.
  • Sancilio & Company Inc
  • Shire Plc
  • MORE
Introduction

Primary Sclerosing Cholangitis - Overview

Primary Sclerosing Cholangitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Primary Sclerosing Cholangitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development

Acorda Therapeutics Inc

Albireo Pharma Inc

Allergan Plc

Conatus Pharmaceuticals Inc

Dr. Falk Pharma GmbH

DURECT Corp

Gilead Sciences Inc

iCo Therapeutics Inc.

Intercept Pharmaceuticals Inc

NGM Biopharmaceuticals Inc

Noxopharm Ltd

Sancilio & Company Inc

Seres Therapeutics Inc

Shenzhen HighTide Biopharmaceutical Ltd

Shire Plc

Sirnaomics Inc

Primary Sclerosing Cholangitis - Drug Profiles

A-4250 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

berberine ursodeoxycholate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bertilimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Metabolic and Gastrointestinal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cenicriviroc - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CM-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DUR-928 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-9674 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTD-1801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDN-7314 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

maralixibat chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGM-282 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

norursodeoxycholic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NYX-205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

obeticholic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-404 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-435 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Autoimmune Hepatitis and Primary Sclerosing Cholangitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STP-705 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

timolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Primary Sclerosing Cholangitis - Dormant Projects

Primary Sclerosing Cholangitis - Discontinued Products

Primary Sclerosing Cholangitis - Product Development Milestones

Featured News & Press Releases

Nov 01, 2017: Intercept Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

Oct 23, 2017: Intercept Announces Positive Results from Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis at The Liver Meeting

Oct 20, 2017: Conatus Pharmaceuticals Announces Poster Presentation at AASLD Annual Meeting

Oct 18, 2017: EMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC

Oct 11, 2017: Intercept Announces Data to be Presented at The Liver Meeting

Sep 25, 2017: Intercept Statement Regarding Ocaliva (obeticholic acid) Safety and Dosing in Primary Biliary Cholangitis Patients

Aug 01, 2017: Sirnaomics Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for the Treatment of Primary Sclerosing Cholangitis

Jul 31, 2017: Intercept Announces Positive Results from the Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis

Jun 26, 2017: FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC

May 19, 2017: Intercept Receives Innovation Award from the National Organization for Rare Disorders for the Development of Ocaliva (obeticholic acid)

Mar 02, 2017: NICE Recommends Ocaliva (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis in England, Wales and Northern Ireland

Jan 05, 2017: Phenex Receives $100 Million Milestone Payment From Gilead

Aug 26, 2016: Biotie: BTT1023 Receives Orphan Drug Designation in the United States

Jun 07, 2016: Immune Pharmaceuticals and Hadasit File a Joint Patent on the Oral Use of Anti-Eotaxin Monoclonal Antibodies, Including Bertilimumab, for the Treatment of GI and Liver Diseases

Apr 16, 2016: Investigational treatment provides hope for some chronic liver disease sufferers

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Primary Sclerosing Cholangitis, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Primary Sclerosing Cholangitis - Pipeline by Acorda Therapeutics Inc, H1

Primary Sclerosing Cholangitis - Pipeline by Albireo Pharma Inc, H1

Primary Sclerosing Cholangitis - Pipeline by Allergan Plc, H1

Primary Sclerosing Cholangitis - Pipeline by Conatus Pharmaceuticals Inc, H1

Primary Sclerosing Cholangitis - Pipeline by Dr. Falk Pharma GmbH, H1

Primary Sclerosing Cholangitis - Pipeline by DURECT Corp, H1

Primary Sclerosing Cholangitis - Pipeline by Gilead Sciences Inc, H1

Primary Sclerosing Cholangitis - Pipeline by iCo Therapeutics Inc., H1

Primary Sclerosing Cholangitis - Pipeline by Intercept Pharmaceuticals Inc, H1

Primary Sclerosing Cholangitis - Pipeline by NGM Biopharmaceuticals Inc, H1

Primary Sclerosing Cholangitis - Pipeline by Noxopharm Ltd, H1

Primary Sclerosing Cholangitis - Pipeline by Sancilio & Company Inc, H1

Primary Sclerosing Cholangitis - Pipeline by Seres Therapeutics Inc, H1

Primary Sclerosing Cholangitis - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H1

Primary Sclerosing Cholangitis - Pipeline by Shire Plc, H1

Primary Sclerosing Cholangitis - Pipeline by Sirnaomics Inc, H1

Primary Sclerosing Cholangitis - Dormant Projects, H1

Primary Sclerosing Cholangitis - Discontinued Products, H1

List of Figures

Number of Products under Development for Primary Sclerosing Cholangitis, H1

Number of Products under Development by Companies, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Acorda Therapeutics Inc
  • Albireo Pharma Inc
  • Allergan Plc
  • Conatus Pharmaceuticals Inc
  • Dr. Falk Pharma GmbH
  • DURECT Corp
  • Gilead Sciences Inc
  • iCo Therapeutics Inc.
  • Intercept Pharmaceuticals Inc
  • NGM Biopharmaceuticals Inc
  • Noxopharm Ltd
  • Sancilio & Company Inc
  • Seres Therapeutics Inc
  • Shenzhen HighTide Biopharmaceutical Ltd
  • Shire Plc
  • Sirnaomics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll